1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Application of ferumoxytol as an MR imaging contrast agent in evaluating brain malignancies
Study TitlePhaseClinical Trial Description
Imaging vascular properties of pediatric brain tumors using ferumoxytol and gadolinium in a single imaging session; an NCI-sponsored exploratory trial (code 7228) (NCT00978562)730To assess the safety and effectiveness of ferumoxytol in improving the ability to image pediatric brain tumors
MRI using ferumoxytol in patients with primary brain cancer or brain metastases from lung or breast cancer; an NCI-sponsored multidisciplinary study (NCT00103038)742Characterization of vascular properties of tumors in the CNS using ferumoxytol for dynamic-susceptibility contrast MRI to compare with those obtained using a gadolinium-based contrast agent for dynamic contrast-enhanced imaging in a single MR imaging session; imaging properties will be assessed longitudinally with up to 6 imaging sessions for 2 years
Magnetic resonance (MR) imaging study using ferumoxytol to assess early tumor response in patients with glioblastoma multiforme (code 7228) (NCT00660543)751Evaluating the ability of ferumoxytol to assess effective early treatment response in glioblastoma multiforme using dynamic perfusion, BBB permeability measurement
Ferumoxytol and gadolinium magnetic resonance imaging (MRI) at 3T and 7T in patients with malignant brain tumors (NCT00659126)762Comparing dynamic perfusion, BBB permeability measurement in 2 different magnetic fields (3T and 7T) in the evaluation of brain tumors; gadolinium and ferumoxytol will be used as contrast agents
Assessing dynamic magnetic resonance (MR) imaging in patients with recurrent high grade glioma receiving chemotherapy (code 7228) (NCT00769093)771Evaluation of imaging changes induced by bevacizumab with dexamethasone in patients with high-grade glioma
MR, histologic and EM imaging of intravenous ferumoxytol in central nervous system (CNS) inflammation (NCT00659776)782Evaluation of the safety and efficacy of ferumoxytol